Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06FQS
|
||||
| Former ID |
DNCL003135
|
||||
| Drug Name |
TGOF02N
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Phase 2 | [1] | ||
| Company |
Fabre-Kramer Pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | 5-HT 2 receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.